Cell and gene therapies are at the forefront of innovation and bring much hope for the future of medicine, they could transform how we treat and potentially cure certain diseases, so the stakes are really high. But they come with new considerations for therapy owners as they are brought to the market. The nature of these treatments and their use of living cells or genetic material create new intricacies and dependencies that disrupt the traditional commercialization process. For the first time, the patient is now part of the supply chain.
“When it comes to cell and gene therapies we are talking about an interconnected and personalized model which requires a higher degree of integration between specialized logistics partners, patient programs, and the health outcomes evidence which is required to drive physician adoption.”, Keegan Moore, Regional Sales Director
In an interview with FreightWaves, Keegan Moore, shares insights about cell and gene therapy commercialization and the shipping requirements therapy developers need to plan for in order to meet patient and provider expectations.